GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aurinia Pharmaceuticals Inc (NAS:AUPH) » Definitions » Total Long-Term Assets

AUPH (Aurinia Pharmaceuticals) Total Long-Term Assets : $108.9 Mil (As of Sep. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Aurinia Pharmaceuticals Total Long-Term Assets?

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Aurinia Pharmaceuticals's Total Long-Term Assets for the quarter that ended in Sep. 2024 was $108.9 Mil.

Aurinia Pharmaceuticals Total Long-Term Assets Historical Data

The historical data trend for Aurinia Pharmaceuticals's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurinia Pharmaceuticals Total Long-Term Assets Chart

Aurinia Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.16 44.23 30.04 28.32 123.26

Aurinia Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 128.54 123.26 118.41 113.86 108.90

Aurinia Pharmaceuticals Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Aurinia Pharmaceuticals Total Long-Term Assets Related Terms

Thank you for viewing the detailed overview of Aurinia Pharmaceuticals's Total Long-Term Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Aurinia Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aurinia Pharmaceuticals Inc (NAS:AUPH) » Definitions » Total Long-Term Assets
Comparable Companies
NVAX OCUL ARVN DAWN NRIX MDXG RCKT RCUS ARDX NTLA VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
IKAP:Germany IKAP:Germany
Address
14315 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6
Website
https://www.auriniapharma.com
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.
Executives
Karen L. Smith director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Jeffrey Allen Bailey director BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Scott Michael Habig officer: Chief Commercial Officer #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
R. Hector Mackay-dunn director #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
Jayne David R.w. director #1203-4464 MARKHAM STREET, VICTORIA A1 BC V8Z7X8
Daniel Billen director #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Jill Leversage director #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Brinda Balakrishnan director #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
Matthew Maxwell Donley officer: Ex VP, Intern'l Operations 4520 EAST WEST HIGHWAY, 3RD FLOOR, BETHESDA MD 20814
Stephen P. Robertson officer: EVP, General Counsel #1203-4464 MARKHAM STREET, VICTORIA A1 BC V8Z7X8
Joseph M Miller officer: Chief Financial Officer C/O CERECOR INC., 400 EAST PRATT STREET, SUITE 606, BALTIMORE MD 21202
Peter Greenleaf director, officer: Chief Executive Officer ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Volker Knappertz officer: EVP, Research and Development SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB249BZ
Robert T Foster director C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Joseph P Hagan director 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037